Advertisement

Topics

STORM Data Show Encouraging Responses, OS With Selinexor/Dexamethasone in Penta-Refractory Myeloma

19:35 EDT 15 Sep 2018 | OncLive

Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.

Original Article: STORM Data Show Encouraging Responses, OS With Selinexor/Dexamethasone in Penta-Refractory Myeloma

NEXT ARTICLE

More From BioPortfolio on "STORM Data Show Encouraging Responses, OS With Selinexor/Dexamethasone in Penta-Refractory Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement